Moore Capital Management, LP Vaxcyte, Inc. Transaction History

Moore Capital Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $587,229 - $1.37 Million	28,534 Added 19.82%	172,500 $8.27 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $1.38 Million - $1.82 Million	63,665 Added 79.28%	143,966 $3.46 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $1.42 Million - $2.13 Million	80,301 New	80,301 $1.75 Million

344

136M

348K

250K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $1.88B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.